Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 30,000 Shares of Stock

Key Points

• Director Blake Borgeson sold 30,000 Recursion Pharmaceuticals shares at an average price of $3.34, generating $100,200. The transaction was made under a pre-arranged Rule 10b5-1 plan, leaving him with 6.16 million shares.
• RXRX recently traded at $3.38, near its 50-day and 200-day moving averages, with a 12-month range of $2.77 to $7.18. The company reported a quarterly loss of $0.25 per share and revenue of $7.67 million, below analyst expectations.
• Analyst sentiment is mixed, with ratings spanning Buy, Hold and Sell; the stock carries an average rating of “Hold” and an average price target of $8.06.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 30,000 shares of the company's stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $3.34, for a total transaction of $100,200.00. Following the completion of the transaction, the director owned 6,158,287 shares in the company, valued at $20,568,678.58. This trade represents a 0.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, August 4th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.25, for a total transaction of $97,500.00.
• On Tuesday, July 7th, Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.96, for a total transaction of $158,400.00.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX traded up $0.05 during trading on Wednesday, reaching $3.38. The company's stock had a trading volume of 14,014,654 shares, compared to its average volume of 18,045,133. The firm has a 50 day moving average price of $3.33 and a 200 day moving average price of $3.34. Recursion Pharmaceuticals, Inc. has a 12 month low of $2.77 and a 12 month high of $7.18. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -3.25 and a beta of 1.07. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.The business had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. During the same period in the prior year, the business posted ($0.41) earnings per share. As a group, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in RXRX. International Assets Investment Management LLC bought a new stake in Recursion Pharmaceuticals during the fourth quarter worth $31,000. Integral Investment Advisors Inc. bought a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at $39,000. Sequoia Financial Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth $41,000. MQS Management LLC acquired a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth $41,000. Finally, Fund Advisors of America Inc FL bought a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter worth $45,000. 89.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on RXRX shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. Morgan Stanley set a $5.30 target price on Recursion Pharmaceuticals in a report on Monday, August 17th. Wall Street Zen raised Recursion Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Saturday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Recursion Pharmaceuticals has an average rating of "Hold" and an average price target of $8.06.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc NASDAQ: RXRX is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source